Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
US6106824A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Aug 2, 1996 |
| Grant date | Aug 22, 2000 |
| Priority date | — |
| Expiry date | Aug 2, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2800/108
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a viral vector capable of the transfer and in vivo expression of growth-associated protein (B-50/GAP-43) in neuronal target cells of a mammalian host. The viral vector contains a recombinant DNA molecule comprising a B-50/GAP-43 gene operably associated with a promoter, which promoter controls short term, high level expression of the B-50/GAP-43 gene. Preferably, the viral vector is a defective viral vector, in particular a defective herpes virus or an adeno-associated virus. In a specific embodiment, defective herpesvirus, adenovirus, and adeno-associated virus viral vectors containing the rat B-50/GAP-43 gene under control of the human cytomegalovirus immediate early promoter have been prepared. The invention further provides a method for treating nerve damage in a subject. The method comprises introducing a vector comprising a B-50/GAP-43 gene operably associated with a promoter into a damaged nerve tissue of a subject. Preferably, the promoter controls short term, high level expression of the B-50/GAP-43 gene, such that the B-50/GAP-43 gene is expressed in the tissue of the subject. Preferably, the vector used in the therapeutic methods of the i…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.